Signaling Pathways - Myosin light chain kinases (MLCKs) - dopamine receptor - CSF1R - Insulin and Insulin-like Receptors
清除全部
-
B5854 Pexidartinib (PLX3397)3 Citation中文名: 培西达替尼Target: FLT3|c-Kit|CSF1RSummary: CSF-1R抑制剂 -
B6506 SCH 23390 hydrochlorideTarget: dopamine receptor|5-HT1 Receptor|5-HT2 ReceptorSummary: 多巴胺受体拮抗剂 -
B6342 H-7 dihydrochlorideTarget: PKC|PKG|PKA|Myosin light chain kinases (MLCKs)Summary: 蛋白激酶抑制剂 -
B3523 Fasudil中文名: 法舒地尔Target: ROCK|PKC|PKG|PKA|Myosin light chain kinases (MLCKs)Summary: 钙拮抗剂 -
A8440 GSK1838705ATarget: Insulin and Insulin-like Receptors|ALKSummary: ATP竞争性IGF-IR/IR/ALK抑制剂 -
A1302 GSK1904529ATarget: Insulin and Insulin-like ReceptorsSummary: IGF-1R/IR 选择性抑制剂 -
A1185 BMS-754807Target: Insulin and Insulin-like ReceptorsSummary: 有效的、选择性的IGF-1R和InsR抑制剂 -
A3626 ML-7 hydrochlorideTarget: Myosin light chain kinases (MLCKs)Summary: 肌球蛋白轻链激酶抑制剂 -
A3608 MK 0893Target: Insulin and Insulin-like Receptors|Glucagon ReceptorsSummary: 胰高血糖素受体/ IGF-1R拮抗剂 -
A4302 Rosiglitazone maleate中文名: 马来酸罗格列酮Target: Insulin and Insulin-like ReceptorsSummary: PPARγ激动剂，有效的胰岛素敏化剂